Murphy & Mullick Capital Management Corp Makes New Investment in Illumina, Inc. (NASDAQ:ILMN)

Murphy & Mullick Capital Management Corp purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 454 shares of the life sciences company’s stock, valued at approximately $61,000.

A number of other large investors also recently made changes to their positions in ILMN. Bank of Stockton grew its holdings in shares of Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after buying an additional 80 shares during the period. Stephens Inc. AR grew its stake in Illumina by 1.4% in the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after acquiring an additional 90 shares during the period. Spire Wealth Management grew its stake in Illumina by 26.0% in the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after acquiring an additional 97 shares during the period. IFP Advisors Inc increased its holdings in shares of Illumina by 19.1% in the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock worth $82,000 after acquiring an additional 99 shares in the last quarter. Finally, Brooklyn Investment Group raised its position in shares of Illumina by 20.5% during the fourth quarter. Brooklyn Investment Group now owns 611 shares of the life sciences company’s stock worth $82,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Shares of Illumina stock opened at $82.28 on Friday. The company has a 50-day simple moving average of $103.93 and a two-hundred day simple moving average of $127.08. Illumina, Inc. has a twelve month low of $80.18 and a twelve month high of $156.66. The stock has a market capitalization of $13.03 billion, a price-to-earnings ratio of -10.71, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on ILMN. TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Robert W. Baird dropped their price target on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. Citigroup cut their price target on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Piper Sandler lifted their target price on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Finally, Stephens reaffirmed an “overweight” rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.